Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Microdosing GLP-1 Medications: Complete Guide to Split Dosing
hubEverything you need to know about microdosing GLP-1 agonists. Split dosing protocols for retatrutide, tirzepatide, and semaglutide to reduce side effects without sacrificing weight loss results.
Microdosing Semaglutide (Ozempic/Wegovy): Evidence-Based Split Dosing Strategies
insightsWhile semaglutide is designed for weekly dosing, its 7-day half-life makes it uniquely suited for split dosing exploration. We examine the pharmacokinetics, protocols, and considerations for microdosing Ozempic and Wegovy.
GLP-1 Microdosing Guide: How to Run a Sub-Standard Protocol
articleA practical how-to guide for running a GLP-1 microdosing protocol on semaglutide or tirzepatide, plus why retatrutide has no lawful microdosing route. Covers approach selection, compound-specific steps, titration decisions, and calculator modeling.
Microdosing Tirzepatide (Mounjaro/Zepbound): Evidence-Based Split Dosing Strategies
insightsWhile tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.